Get the Stockscreener App
2.99
1.36%
0.04
Entera Bio Ltd stock is traded at $2.99, with a volume of 1.05M.
It is up +1.36% in the last 24 hours and up +68.93% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
See More
Previous Close:
$2.95
Open:
$2.95
24h Volume:
1.05M
Relative Volume:
0.46
Market Cap:
$147.38M
Revenue:
$42,000
Net Income/Loss:
$-12.38M
P/E Ratio:
-11.35
EPS:
-0.2634
Net Cash Flow:
$-9.61M
1W Performance:
+45.85%
1M Performance:
+68.93%
6M Performance:
+118.25%
1Y Performance:
+54.92%
1-Day Range:
$2.92
$3.20
1-Week Range:
$2.6607
$4.20
52-Week Range:
$0.91
$4.20
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
2.99 | 193.22M | 42,000 | -12.38M | -9.61M | -0.2634 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
ENTX|Entera Bio Ltd|Price:3.930|Chg%:+1.880 - TradingKey
Entera Bio Ltd. announced that it expects to receive $274.999977 million in funding from a group of investors - marketscreener.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Entera Bio Shares Climb on $275M Private Placement - Moomoo
Entera Bio Ltd (ENTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Entera Bio raises $275m for Phase III osteoporosis drug trialGlobes - Globes - Israel Business News
Entera Bio raises $275 million in private placement for phase 3 - Investing.com
ENTX Stock Explodes Higher As Traders Pounce On Breakout - StocksToTrade
Entera Bio stock surges on $275M private placement - Investing.com
Entera Bio raises $275 million in private placement - Investing.com
Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement - TradingView
Entera Bio raises $275 million in private placement By Investing.com - Investing.com Canada
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement - Yahoo Finance
Entera Bio Ltd (ENTX) Cash Flow - TradingKey
Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entera Bio Ltd (ENTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entera Bio Ltd (ENTX) Income Statement - TradingKey
Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Entera Bio Ltd (ENTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entera Bio Leads Our Top 3 Penny Stocks To Consider - Sahm
Entera Bio Ltd. (ENTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know - Yahoo Finance
Entera Bio Expands Share Authorization and Equity Plans - TipRanks
Entera Bio Ltd. Approves Director Compensation, Share-Based Plans, and Capital Increase at 2026 Annual Meeting - Minichart
Entera Bio (NASDAQ: ENTX) expands share authorization and equity plan pool - Stock Titan
Entera Bio (NASDAQ: ENTX) CEO swaps cash for stock-settled RSUs - Stock Titan
Entera Bio shareholders approve authorized share increase at annual meeting - Bitget
After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? - TipRanks
After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? - Benzinga
Entera Bio (ENTX) Slips Slightly as Stock Hovers Near Key Support LevelLast Point Resistance - dars.gov.et
America’s Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX) - TipRanks
America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX) - Benzinga
ENTX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseEarnings Volatility Report - dars.gov.et
Take the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in Focus - TradingView
Price to earnings forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to earnings forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to sales forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – FWB:5DT - TradingView
Enterprise value to EBIT forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Price to book forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView
Price to sales forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Enterprise value to revenue forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView
Entera Bio Ltd. Actuals & Estimates (HAM:5DT) - TradingView
ENTX Forecast — Price Target — Prediction for 2027 - TradingView
5DT Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback - Investing.com UK
H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback By Investing.com - Investing.com Australia
H.C. Wainwright Maintains Entera Bio(ENTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market - GlobeNewswire Inc.
3 Promising Penny Stocks With Market Caps Under $600M - simplywall.st
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entera Bio Ltd Stock (ENTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ellis Sean | Director |
Mar 05 '26 |
Buy |
1.23 |
10,000 |
12,300 |
188,098 |
| Rubin Steven D | Director |
Feb 12 '26 |
Buy |
1.49 |
5,000 |
7,450 |
15,000 |
| Rubin Steven D | Director |
Feb 09 '26 |
Buy |
1.20 |
10,000 |
12,000 |
10,000 |
| Ellis Sean | Director |
Feb 09 '26 |
Buy |
1.24 |
18,000 |
22,320 |
178,098 |
| Toledano Miranda Jayne | Chief Executive Officer |
Dec 29 '25 |
Buy |
1.81 |
11,000 |
19,912 |
426,575 |
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):